DCGI approves Bharat Biotech’s COVAXIN for Phase II/III clinical trial in 2-18 years

Delhi, May 13: The Drugs Controller General of India (DCGI) – the national regulator of the country, after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat […]

Continue Reading

DCGI approves anti-COVID drug developed by DRDO for emergency use

Delhi, May 8: An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad, said an official release. According to a statement of the Ministry of Defence, clinical […]

Continue Reading